Last reviewed · How we verify

Epithelium-On Riboflavin

Crowd Health Research, LTD · Phase 3 active Small molecule

Epithelium-on riboflavin uses riboflavin (vitamin B2) with ultraviolet light exposure to strengthen corneal collagen cross-linking while preserving the corneal epithelium.

Epithelium-on riboflavin uses riboflavin (vitamin B2) with ultraviolet light exposure to strengthen corneal collagen cross-linking while preserving the corneal epithelium. Used for Corneal ectasia (keratoconus, post-refractive surgery ectasia), Corneal weakening and progressive myopia.

At a glance

Generic nameEpithelium-On Riboflavin
Also known asVitamin B2
SponsorCrowd Health Research, LTD
Drug classCorneal cross-linking agent
TargetCorneal collagen (photochemical cross-linking via riboflavin and UVA)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

This approach combines riboflavin photosensitization with UVA light to induce collagen cross-linking in the cornea, similar to standard corneal cross-linking (CXL) but maintains the corneal epithelium intact rather than removing it. By preserving the epithelial barrier, the technique aims to reduce postoperative pain, accelerate healing, and maintain corneal clarity while achieving biomechanical strengthening of the stroma.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: